New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›Invesco›PBE

PBE

Invesco Dynamic Biotechnology & Genome ETF

Passive ETF Equity Theme: BioTech & Genomics

The PBE Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Biotech & Genome Intellidex Index. The PBE ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

$90.52

-$0.65 (-0.71%) yesterday

7:59 PM 07/13/26 Open

1D price range

$89.89$90.56

52W price range

$64.00$93.28

YTD Perf.

+11.51%

YTD Flows

Annualized volatility

Fund AuM

€250M

Share class AuM

€250M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US46137V7872

TER

0.58%

Inception date

6/23/2005

Issuer

Invesco

Benchmark

Dynamic Biotech & Genome Intellidex Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	-2.35%
FBT First Trust NYSE Arca Biotechnology ETF	-3.51%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	-3.14%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	-1.48%
PJP Invesco Dynamic Pharmaceuticals ETF	-2.12%
EDOC Global X Telemedicine & Digital Health UCITS ETF	-1.56%
XHE State Street SPDR S&P Health Care Equipment ETF	-0.77%
IHI iShares U.S. Medical Devices ETF	-1.48%
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	-4.91%
DOCG L&G Healthcare Technology & Innovation UCITS ETF	-2.24%
HTEC Robo Global Healthcare Technology and Innovation ETF	-1.98%
FTXH First Trust Nasdaq Pharmaceuticals ETF	-2.22%
CURE Global X S&P Biotech ETF	-3.31%
XBI State Street SPDR S&P Biotech ETF	-3.34%
BTEC iShares Nasdaq US Biotechnology UCITS ETF	-2.94%

API

PerformanceDec 31, 2025 - Jul 13, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

100.00%

Latest PBE news

No content available for this fund

FAQ about PBE

PBE is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.

PBE tracks the Dynamic Biotech & Genome Intellidex TR Index - USD, through a full replication replication method.

PBE carries a total expense ratio (TER) of 0.58%, indicating the annual cost for holding the fund.

PBE was introduced to the market on June 23, 2005. It trades on United States

Invesco Dynamic Biotechnology & Genome ETF, PBE, is provided by Invesco. Learn more about Invesco here.

PBE oversees €250M in assets as of July 13, 2026.

PBE follows a distributing dividend policy, meaning it pays out income to investors. As of July 13, 2026, its 12-month trailing yield was 1.71%.

As of May 31, 2026, PBE has significant geographic allocations in USA and Netherlands.

As of May 31, 2026, PBE focuses largely on Healthcare.

As of May 31, 2026, PBE holds 30 positions in its portfolio, with 62.89% of assets concentrated in its top 15 holdings.

As of May 31, 2026, PBE top three holdings include Illumina, Inc., United Therapeutics Corp. and Biogen, Inc..

The base currency of PBE is USD.

Top 10 holdings

Data as of 05/31/26

Illumina, Inc.

6.37%

United Therapeutics Corp.

5.86%

Biogen, Inc.

4.97%

Incyte Corp.

4.76%

Gilead Sciences, Inc.

4.55%

Alnylam Pharmaceuticals, Inc.

4.52%

Amgen, Inc.

4.34%

Regeneron Pharmaceuticals, Inc.

3.97%

Veracyte, Inc.

3.62%

Catalyst Pharmaceuticals, Inc.

3.48%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

Invesco Dynamic Biotechnology & Genome ETF

FAQ about PBE

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US